Cargando…

Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study

INTRODUCTION: Type II endoleak (EL) is frequently seen after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) and is often considered responsible for aneurysm sac enlargement if it persists. In order to reduce type II EL and consequent sac enlargement, pre-emptive embolisation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichihashi, Shigeo, Takahara, Mitsuyoshi, Fujimura, Naoki, Nagatomi, Satoru, Iwakoshi, Shinichi, Bolstad, Francesco, Kichikawa, Kimihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044938/
https://www.ncbi.nlm.nih.gov/pubmed/32066599
http://dx.doi.org/10.1136/bmjopen-2019-031758
_version_ 1783501674475683840
author Ichihashi, Shigeo
Takahara, Mitsuyoshi
Fujimura, Naoki
Nagatomi, Satoru
Iwakoshi, Shinichi
Bolstad, Francesco
Kichikawa, Kimihiko
author_facet Ichihashi, Shigeo
Takahara, Mitsuyoshi
Fujimura, Naoki
Nagatomi, Satoru
Iwakoshi, Shinichi
Bolstad, Francesco
Kichikawa, Kimihiko
author_sort Ichihashi, Shigeo
collection PubMed
description INTRODUCTION: Type II endoleak (EL) is frequently seen after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) and is often considered responsible for aneurysm sac enlargement if it persists. In order to reduce type II EL and consequent sac enlargement, pre-emptive embolisation of the inferior mesenteric artery (IMA), which is a main source for persistent type II EL, has been introduced in many vascular centres. At present, there is a lack of robust evidence to support the efficacy of pre-emptive embolisation of IMA on reduction of persistent type II EL with subsequent sac shrinkage. METHOD AND ANALYSIS: This multicentre, randomised controlled trial will recruit 200 patients who have fusiform AAA ≥50 mm/rapidly enlarging fusiform AAA, with patent IMA, and randomly allocate them either to a pre-emptive IMA embolisation group or non-embolisation control group in a ratio of 1:1. The primary endpoint is the difference of aneurysm sac volume change assessed by CT scans between the pre-emptive IMA embolisation group and the control group at 12 months after EVAR. The secondary endpoints are defined as change of aneurysm sac volume in both groups at 6 and 24 months, freedom from sac enlargement at 12 and 24 months after EVAR, prevalence of type II EL at 1, 6, 12 and 24 months evaluated by contrast-enhanced CT, reintervention rate, aneurysm related mortality, overall survival, perioperative morbidity, volume of contrast media used during EVAR and dosage of radiation. ETHICS AND DISSEMINATION: The protocol has been reviewed and approved by the ethics committee of Nara Medical University (No. 2113). The findings of this study will be communicated to healthcare professionals, participants and the public through peer-reviewed publications, scientific conferences and the University Hospital Medical Information Network Clinical Trials Registry home page. TRIAL REGISTRATION NUMBER: UMIN000035502.
format Online
Article
Text
id pubmed-7044938
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70449382020-03-09 Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study Ichihashi, Shigeo Takahara, Mitsuyoshi Fujimura, Naoki Nagatomi, Satoru Iwakoshi, Shinichi Bolstad, Francesco Kichikawa, Kimihiko BMJ Open Cardiovascular Medicine INTRODUCTION: Type II endoleak (EL) is frequently seen after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) and is often considered responsible for aneurysm sac enlargement if it persists. In order to reduce type II EL and consequent sac enlargement, pre-emptive embolisation of the inferior mesenteric artery (IMA), which is a main source for persistent type II EL, has been introduced in many vascular centres. At present, there is a lack of robust evidence to support the efficacy of pre-emptive embolisation of IMA on reduction of persistent type II EL with subsequent sac shrinkage. METHOD AND ANALYSIS: This multicentre, randomised controlled trial will recruit 200 patients who have fusiform AAA ≥50 mm/rapidly enlarging fusiform AAA, with patent IMA, and randomly allocate them either to a pre-emptive IMA embolisation group or non-embolisation control group in a ratio of 1:1. The primary endpoint is the difference of aneurysm sac volume change assessed by CT scans between the pre-emptive IMA embolisation group and the control group at 12 months after EVAR. The secondary endpoints are defined as change of aneurysm sac volume in both groups at 6 and 24 months, freedom from sac enlargement at 12 and 24 months after EVAR, prevalence of type II EL at 1, 6, 12 and 24 months evaluated by contrast-enhanced CT, reintervention rate, aneurysm related mortality, overall survival, perioperative morbidity, volume of contrast media used during EVAR and dosage of radiation. ETHICS AND DISSEMINATION: The protocol has been reviewed and approved by the ethics committee of Nara Medical University (No. 2113). The findings of this study will be communicated to healthcare professionals, participants and the public through peer-reviewed publications, scientific conferences and the University Hospital Medical Information Network Clinical Trials Registry home page. TRIAL REGISTRATION NUMBER: UMIN000035502. BMJ Publishing Group 2020-02-16 /pmc/articles/PMC7044938/ /pubmed/32066599 http://dx.doi.org/10.1136/bmjopen-2019-031758 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cardiovascular Medicine
Ichihashi, Shigeo
Takahara, Mitsuyoshi
Fujimura, Naoki
Nagatomi, Satoru
Iwakoshi, Shinichi
Bolstad, Francesco
Kichikawa, Kimihiko
Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study
title Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study
title_full Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study
title_fullStr Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study
title_full_unstemmed Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study
title_short Multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of Clarify IMA study
title_sort multicentre randomised controlled trial to evaluate the efficacy of pre-emptive inferior mesenteric artery embolisation during endovascular aortic aneurysm repair on aneurysm sac change: protocol of clarify ima study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044938/
https://www.ncbi.nlm.nih.gov/pubmed/32066599
http://dx.doi.org/10.1136/bmjopen-2019-031758
work_keys_str_mv AT ichihashishigeo multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy
AT takaharamitsuyoshi multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy
AT fujimuranaoki multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy
AT nagatomisatoru multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy
AT iwakoshishinichi multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy
AT bolstadfrancesco multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy
AT kichikawakimihiko multicentrerandomisedcontrolledtrialtoevaluatetheefficacyofpreemptiveinferiormesentericarteryembolisationduringendovascularaorticaneurysmrepaironaneurysmsacchangeprotocolofclarifyimastudy